SLC22A3 and colorectal cancer: Higher pre-treatment intratumoral SLC22A3 protein expression was observed in colorectal cancer patients responding to adjuvant chemotherapy with FOLFOX (combination of 5-fluorouracil, folinic acid and oxaliplatin) regimen than in non-responders19 suggesting a potential predictive character of this biomarker.